Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis.
Identifieur interne : 000514 ( Main/Exploration ); précédent : 000513; suivant : 000515Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis.
Auteurs : Nashmil Ghadimi [Iran] ; Sara Kaveh [Iran] ; Hossein Shabaninejad [Royaume-Uni] ; Alaadine Lijassi [Maroc] ; Ali Zahed Mehr [Iran] ; Hossein Hosseinifard [Iran]Source :
- International journal of clinical pharmacy [ 2210-7711 ] ; 2019.
Descripteurs français
- KwdFr :
- Agents cardiovasculaires (pharmacologie), Agents cardiovasculaires (usage thérapeutique), Antagonistes bêta-adrénergiques (pharmacologie), Antagonistes bêta-adrénergiques (usage thérapeutique), Essais contrôlés randomisés comme sujet (méthodes), Humains (MeSH), Ivabradine (pharmacologie), Ivabradine (usage thérapeutique), Rythme cardiaque (effets des médicaments et des substances chimiques), Rythme cardiaque (physiologie), Résultat thérapeutique (MeSH), Sténose mitrale (diagnostic), Sténose mitrale (traitement médicamenteux), Sténose mitrale (épidémiologie), Troubles du rythme cardiaque (diagnostic), Troubles du rythme cardiaque (traitement médicamenteux), Troubles du rythme cardiaque (épidémiologie).
- MESH :
- diagnostic : Sténose mitrale, Troubles du rythme cardiaque.
- effets des médicaments et des substances chimiques : Rythme cardiaque.
- méthodes : Essais contrôlés randomisés comme sujet.
- pharmacologie : Agents cardiovasculaires, Antagonistes bêta-adrénergiques, Ivabradine.
- physiologie : Rythme cardiaque.
- traitement médicamenteux : Sténose mitrale, Troubles du rythme cardiaque.
- usage thérapeutique : Agents cardiovasculaires, Antagonistes bêta-adrénergiques, Ivabradine.
- épidémiologie : Sténose mitrale, Troubles du rythme cardiaque.
- Humains, Résultat thérapeutique.
English descriptors
- KwdEn :
- Adrenergic beta-Antagonists (pharmacology), Adrenergic beta-Antagonists (therapeutic use), Arrhythmias, Cardiac (diagnosis), Arrhythmias, Cardiac (drug therapy), Arrhythmias, Cardiac (epidemiology), Cardiovascular Agents (pharmacology), Cardiovascular Agents (therapeutic use), Heart Rate (drug effects), Heart Rate (physiology), Humans (MeSH), Ivabradine (pharmacology), Ivabradine (therapeutic use), Mitral Valve Stenosis (diagnosis), Mitral Valve Stenosis (drug therapy), Mitral Valve Stenosis (epidemiology), Randomized Controlled Trials as Topic (methods), Treatment Outcome (MeSH).
- MESH :
- chemical , pharmacology : Adrenergic beta-Antagonists, Cardiovascular Agents, Ivabradine.
- chemical , therapeutic use : Adrenergic beta-Antagonists, Cardiovascular Agents, Ivabradine.
- diagnosis : Arrhythmias, Cardiac, Mitral Valve Stenosis.
- drug effects : Heart Rate.
- drug therapy : Arrhythmias, Cardiac, Mitral Valve Stenosis.
- epidemiology : Arrhythmias, Cardiac, Mitral Valve Stenosis.
- methods : Randomized Controlled Trials as Topic.
- physiology : Heart Rate.
- Humans, Treatment Outcome.
Abstract
Background Patients with mitral valve stenosis have increased heart rate. HR reduction is known as an important treatment and therapy strategy for patients with mitral valve stenosis. Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm. Methods Randomized controlled trials were searched in Cochrane Library, PubMed, Web of Science, CRD, Scopus, and Google Scholar with no start time limitation and ending June 2018. Risk of bias across was assessed by the Cochrane Risk of Bias Assessment tool. Fixed effects models were used to combine the results and the mean difference with a 95% confidence interval. This meta-analysis was performed using Meta Package in R software. Results Five studies entered meta-analysis. The total number of patients treated with ivabradine and beta-blockers was 178 and 178 respectively. The results showed that the mean of maximum HR and HR at rest was lower at about 5.03 units and upper 4.32 units respectively with use of ivabradine compared with the use of beta-blockers. These values were statistically significant. Conclusion It seems that the efficacy of ivabradine is good in comparison with betablockers, but it still requires more clinical trials.
DOI: 10.1007/s11096-018-00778-z
PubMed: 30659493
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000294
- to stream PubMed, to step Curation: 000293
- to stream PubMed, to step Checkpoint: 000274
- to stream Main, to step Merge: 000514
- to stream Main, to step Curation: 000514
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis.</title><author><name sortKey="Ghadimi, Nashmil" sort="Ghadimi, Nashmil" uniqKey="Ghadimi N" first="Nashmil" last="Ghadimi">Nashmil Ghadimi</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Kaveh, Sara" sort="Kaveh, Sara" uniqKey="Kaveh S" first="Sara" last="Kaveh">Sara Kaveh</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Shabaninejad, Hossein" sort="Shabaninejad, Hossein" uniqKey="Shabaninejad H" first="Hossein" last="Shabaninejad">Hossein Shabaninejad</name><affiliation wicri:level="1"><nlm:affiliation>Health Economics Group, Institute of Health & Society, Newcastle University, Newcastle, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics Group, Institute of Health & Society, Newcastle University, Newcastle</wicri:regionArea><wicri:noRegion>Newcastle</wicri:noRegion></affiliation></author><author><name sortKey="Lijassi, Alaadine" sort="Lijassi, Alaadine" uniqKey="Lijassi A" first="Alaadine" last="Lijassi">Alaadine Lijassi</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat</wicri:regionArea><placeName><settlement type="city">Rabat</settlement><region nuts="2">Rabat-Salé-Kénitra</region></placeName></affiliation></author><author><name sortKey="Mehr, Ali Zahed" sort="Mehr, Ali Zahed" uniqKey="Mehr A" first="Ali Zahed" last="Mehr">Ali Zahed Mehr</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Hosseinifard, Hossein" sort="Hosseinifard, Hossein" uniqKey="Hosseinifard H" first="Hossein" last="Hosseinifard">Hossein Hosseinifard</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. hosseinefard@gmail.com.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:30659493</idno><idno type="pmid">30659493</idno><idno type="doi">10.1007/s11096-018-00778-z</idno><idno type="wicri:Area/PubMed/Corpus">000294</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000294</idno><idno type="wicri:Area/PubMed/Curation">000293</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000293</idno><idno type="wicri:Area/PubMed/Checkpoint">000274</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000274</idno><idno type="wicri:Area/Main/Merge">000514</idno><idno type="wicri:Area/Main/Curation">000514</idno><idno type="wicri:Area/Main/Exploration">000514</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis.</title><author><name sortKey="Ghadimi, Nashmil" sort="Ghadimi, Nashmil" uniqKey="Ghadimi N" first="Nashmil" last="Ghadimi">Nashmil Ghadimi</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Kaveh, Sara" sort="Kaveh, Sara" uniqKey="Kaveh S" first="Sara" last="Kaveh">Sara Kaveh</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Shabaninejad, Hossein" sort="Shabaninejad, Hossein" uniqKey="Shabaninejad H" first="Hossein" last="Shabaninejad">Hossein Shabaninejad</name><affiliation wicri:level="1"><nlm:affiliation>Health Economics Group, Institute of Health & Society, Newcastle University, Newcastle, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Health Economics Group, Institute of Health & Society, Newcastle University, Newcastle</wicri:regionArea><wicri:noRegion>Newcastle</wicri:noRegion></affiliation></author><author><name sortKey="Lijassi, Alaadine" sort="Lijassi, Alaadine" uniqKey="Lijassi A" first="Alaadine" last="Lijassi">Alaadine Lijassi</name><affiliation wicri:level="3"><nlm:affiliation>Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat, Morocco.</nlm:affiliation><country xml:lang="fr">Maroc</country><wicri:regionArea>Faculty of Medicine and Pharmacy of Rabat, Mohammed V University of Rabat, Rabat</wicri:regionArea><placeName><settlement type="city">Rabat</settlement><region nuts="2">Rabat-Salé-Kénitra</region></placeName></affiliation></author><author><name sortKey="Mehr, Ali Zahed" sort="Mehr, Ali Zahed" uniqKey="Mehr A" first="Ali Zahed" last="Mehr">Ali Zahed Mehr</name><affiliation wicri:level="1"><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Hosseinifard, Hossein" sort="Hosseinifard, Hossein" uniqKey="Hosseinifard H" first="Hossein" last="Hosseinifard">Hossein Hosseinifard</name><affiliation wicri:level="1"><nlm:affiliation>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran, Iran. hosseinefard@gmail.com.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Health Management and Economics Research Center, Iran University of Medical Sciences, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></analytic><series><title level="j">International journal of clinical pharmacy</title><idno type="eISSN">2210-7711</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic beta-Antagonists (pharmacology)</term><term>Adrenergic beta-Antagonists (therapeutic use)</term><term>Arrhythmias, Cardiac (diagnosis)</term><term>Arrhythmias, Cardiac (drug therapy)</term><term>Arrhythmias, Cardiac (epidemiology)</term><term>Cardiovascular Agents (pharmacology)</term><term>Cardiovascular Agents (therapeutic use)</term><term>Heart Rate (drug effects)</term><term>Heart Rate (physiology)</term><term>Humans (MeSH)</term><term>Ivabradine (pharmacology)</term><term>Ivabradine (therapeutic use)</term><term>Mitral Valve Stenosis (diagnosis)</term><term>Mitral Valve Stenosis (drug therapy)</term><term>Mitral Valve Stenosis (epidemiology)</term><term>Randomized Controlled Trials as Topic (methods)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents cardiovasculaires (pharmacologie)</term><term>Agents cardiovasculaires (usage thérapeutique)</term><term>Antagonistes bêta-adrénergiques (pharmacologie)</term><term>Antagonistes bêta-adrénergiques (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet (méthodes)</term><term>Humains (MeSH)</term><term>Ivabradine (pharmacologie)</term><term>Ivabradine (usage thérapeutique)</term><term>Rythme cardiaque (effets des médicaments et des substances chimiques)</term><term>Rythme cardiaque (physiologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Sténose mitrale (diagnostic)</term><term>Sténose mitrale (traitement médicamenteux)</term><term>Sténose mitrale (épidémiologie)</term><term>Troubles du rythme cardiaque (diagnostic)</term><term>Troubles du rythme cardiaque (traitement médicamenteux)</term><term>Troubles du rythme cardiaque (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adrenergic beta-Antagonists</term><term>Cardiovascular Agents</term><term>Ivabradine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic beta-Antagonists</term><term>Cardiovascular Agents</term><term>Ivabradine</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Arrhythmias, Cardiac</term><term>Mitral Valve Stenosis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Sténose mitrale</term><term>Troubles du rythme cardiaque</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Heart Rate</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arrhythmias, Cardiac</term><term>Mitral Valve Stenosis</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Rythme cardiaque</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Arrhythmias, Cardiac</term><term>Mitral Valve Stenosis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Essais contrôlés randomisés comme sujet</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents cardiovasculaires</term><term>Antagonistes bêta-adrénergiques</term><term>Ivabradine</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Rythme cardiaque</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Heart Rate</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sténose mitrale</term><term>Troubles du rythme cardiaque</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents cardiovasculaires</term><term>Antagonistes bêta-adrénergiques</term><term>Ivabradine</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Sténose mitrale</term><term>Troubles du rythme cardiaque</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background Patients with mitral valve stenosis have increased heart rate. HR reduction is known as an important treatment and therapy strategy for patients with mitral valve stenosis. Aim of the review The aim of this systematic review and meta-analysis was to compare the efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm. Methods Randomized controlled trials were searched in Cochrane Library, PubMed, Web of Science, CRD, Scopus, and Google Scholar with no start time limitation and ending June 2018. Risk of bias across was assessed by the Cochrane Risk of Bias Assessment tool. Fixed effects models were used to combine the results and the mean difference with a 95% confidence interval. This meta-analysis was performed using Meta Package in R software. Results Five studies entered meta-analysis. The total number of patients treated with ivabradine and beta-blockers was 178 and 178 respectively. The results showed that the mean of maximum HR and HR at rest was lower at about 5.03 units and upper 4.32 units respectively with use of ivabradine compared with the use of beta-blockers. These values were statistically significant. Conclusion It seems that the efficacy of ivabradine is good in comparison with betablockers, but it still requires more clinical trials.</div></front></TEI><affiliations><list><country><li>Iran</li><li>Maroc</li><li>Royaume-Uni</li></country><region><li>Rabat-Salé-Kénitra</li></region><settlement><li>Rabat</li></settlement></list><tree><country name="Iran"><noRegion><name sortKey="Ghadimi, Nashmil" sort="Ghadimi, Nashmil" uniqKey="Ghadimi N" first="Nashmil" last="Ghadimi">Nashmil Ghadimi</name></noRegion><name sortKey="Hosseinifard, Hossein" sort="Hosseinifard, Hossein" uniqKey="Hosseinifard H" first="Hossein" last="Hosseinifard">Hossein Hosseinifard</name><name sortKey="Kaveh, Sara" sort="Kaveh, Sara" uniqKey="Kaveh S" first="Sara" last="Kaveh">Sara Kaveh</name><name sortKey="Mehr, Ali Zahed" sort="Mehr, Ali Zahed" uniqKey="Mehr A" first="Ali Zahed" last="Mehr">Ali Zahed Mehr</name></country><country name="Royaume-Uni"><noRegion><name sortKey="Shabaninejad, Hossein" sort="Shabaninejad, Hossein" uniqKey="Shabaninejad H" first="Hossein" last="Shabaninejad">Hossein Shabaninejad</name></noRegion></country><country name="Maroc"><region name="Rabat-Salé-Kénitra"><name sortKey="Lijassi, Alaadine" sort="Lijassi, Alaadine" uniqKey="Lijassi A" first="Alaadine" last="Lijassi">Alaadine Lijassi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/MaghrebDataLibMedV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000514 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000514 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= MaghrebDataLibMedV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:30659493
|texte= Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:30659493" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a MaghrebDataLibMedV2
| This area was generated with Dilib version V0.6.38. |  |